Supernus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Supernus Pharmaceuticals

09/05/2023 23:20

* Supernus Pharmaceuticals Inc  SUPN.OQ  reported quarterly
adjusted earnings of 29 cents​​ per share for the quarter ended
in March. The mean expectation of four analysts for the quarter
was for earnings of 17 cents per share.
    * Revenue rose 0.8% to $153.76 million from a year ago;
analysts
expected $139.02 million. 
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates 
    * Supernus Pharmaceuticals Inc shares had risen by 1.5% this
quarter and gained 3.1% so far this year.
    * Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $44.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
9 at 10:20 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      0.17           0.29           Beat
 Dec. 31 2022      0.68           0.43           Missed
 Sep. 30 2022      0.36           0.03           Missed
 Jun. 30 2022      0.29           0.14           Missed